SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients—A Single-Center Experience

Immunocompromised patients experience reduced vaccine effectiveness and are at higher risk for coronavirus disease 19 (COVID-19) death. Pre-exposure prophylaxis (PrEP) aims to protect these patients. So far, only tixagevimab/cilgavimab is authorized for use as PrEP. This paper aims to provide real-w...

Descripción completa

Detalles Bibliográficos
Autores principales: Totschnig, David, Augustin, Max, Niculescu, Iulia, Laferl, Hermann, Jansen-Skoupy, Sonja, Lehmann, Clara, Wenisch, Christoph, Zoufaly, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607212/
https://www.ncbi.nlm.nih.gov/pubmed/36298832
http://dx.doi.org/10.3390/v14102278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607212/
https://www.ncbi.nlm.nih.gov/pubmed/36298832
http://dx.doi.org/10.3390/v14102278

Ejemplares similares